The Expert Committee on vaccine administration under the chairmanship of NITI Aayog member Dr V K Paul will meet on Wednesday to consider the logistics and ethical aspects of procurement and administration of COVID-19 vaccine, said the Union Ministry of Health and Family Welfare.
The Committee will engage with all the stakeholders including state governments and vaccine manufacturers. “The Expert Committee on Vaccine Administration under the chairmanship of Dr V K Paul, NITI Aayog will meet on 12th August to consider logistics & ethical aspects of procurement & administration of COVID-19 vaccine,” the Ministry tweeted.
ALSO READ: Serum Institute to produce up to 100 million doses of COVID-19 vaccine for India & other countries
“The Committee will engage with all the stakeholders including State governments and vaccine manufacturers,” it said in another tweet.
The Committee will engage with all the stakeholders including State governments and vaccine manufacturers.@PMOIndia @drharshvardhan @AshwiniKChoubey @PIB_India @DDNewslive @airnewsalerts @COVIDNewsByMIB @CovidIndiaSeva @ICMRDELHI @NITIAayog @PTI_News @ANI
— Ministry of Health (@MoHFW_INDIA) August 11, 2020
According to the Indian Council of Medical Research (ICMR), three Indian COVID-19 vaccines are in different phases of clinical testing at present.
“At the present moment, we have three Indian vaccines that are in different phases of clinical testing. The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine,” said top ICMR scientist Prof Balram Bhargava.
“Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites,” he added.
India’s COVID-19 count has crossed 22 lakh-mark including 6,34,945 active cases, 15,35,744 cured/discharged/migrated while the cumulative toll reached 44,386.
However, the Health Ministry has pointed out that the infection is now concentrated in 10 States that contribute more than 80 per cent of the new cases.